The Direxion Daily Pharmaceutical & Medical Bull 3X Shares ETF (PILL) seeks daily investment results, before fees and expenses, equal to 300% of the performance of the S&P Pharmaceuticals Select Industry Index. That index serves as a modified equal-weighted benchmark for stocks within the S&P Total Market Index classified under the pharmaceuticals sub-industry of the Global Industry Classification Standard (GICS).
PILL holds roughly 75 underlying pharmaceutical names and operates as a non-diversified fund that obtains its leverage primarily through swap agreements and other financial instruments rather than direct borrowing. Because the index is equal-weighted, top holdings such as Axsome Therapeutics (AXSM), Eli Lilly (LLY), Merck (MRK), and Viatris (VTRS) each represent only about 2% of the index. The fund carries a net expense ratio of roughly 0.97% and maintains a relatively small asset base, with assets under management in the low tens of millions of dollars.
This structure helps explain much of PILL's recent behavior. With exposure spread across small-, mid-, and large-cap pharmaceutical companies and leverage reset daily, the fund tends to show outsized short-term volatility compared to a standard sector fund, especially when the underlying index moves sharply.
Over the trailing 30 days, PILL declined approximately 13%, moving from a closing price near $15.08 to about $13.08. The path was choppy rather than steady, with the fund ranging between roughly $13.40 and $17.99 before giving back gains into the latest close. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
The three-month picture looks considerably weaker. PILL fell about 43% over the last quarter, dropping from a level near $22.82 to $13.08. This shows that the recent 30-day decline forms part of a longer downtrend rather than an isolated move, which aligns with a leveraged product tracking an index under sustained selling pressure.
The main driver of PILL's decline is the performance of the underlying S&P Pharmaceuticals Select Industry Index, amplified by 3x daily leverage. When the benchmark falls, PILL's daily reset mechanism magnifies those losses, and repeated down days erode value more than a simple cumulative index move would indicate.
The equal-weighted design also plays a role. Smaller, higher-beta biopharma and specialty pharmaceutical names receive the same weighting as larger, more stable firms, making the index more sensitive to shifts in risk appetite. Weakness in these more volatile constituents contributed to broader drawdowns in the benchmark, which PILL then magnified threefold on a daily basis.
Macro conditions added further pressure. Ongoing scrutiny of drug pricing and healthcare policy, along with shifting investor preferences away from defensive sectors during risk-on periods, weighed on the pharmaceuticals group. Elevated interest-rate expectations can also affect longer-duration growth-oriented biopharma names, contributing to the choppy price action seen in PILL.
The quarterly decline reflects a broader rotation out of pharmaceutical equities that has continued for several months. Investors have favored other sectors and themes, while regulatory uncertainty around drug pricing and Medicare negotiation has remained a structural overhang.
Because PILL is a daily-reset leveraged product, the longer the underlying index stays under pressure or trades in a volatile range, the more pronounced the negative compounding effect becomes. This helps explain why the fund's quarterly loss of roughly 43% exceeds a simple three-times multiple of the index's own decline. Institutional flows out of leveraged pharmaceutical exposure have also kept average trading volumes modest, reflecting reduced conviction in the sector over the period.
Looking ahead, several factors are likely to influence PILL's path. The most important remains the direction of the underlying pharmaceutical index, since leverage will continue to amplify daily moves in either direction. Investors should monitor policy developments around drug pricing and healthcare regulation, which have repeatedly shaped sector sentiment, as well as earnings results from major index constituents.
Interest-rate expectations and broader risk appetite will also matter, particularly for the smaller, higher-beta biopharma names that carry outsized influence in an equal-weighted benchmark. Finally, because PILL resets exposure daily, holding-period volatility and the risk of compounding losses remain structural considerations that warrant attention. These themes, rather than any single data point, are likely to drive the fund's behavior in the months ahead.
In my own research, I often turn to Tickeron's AI-powered platforms to scan for patterns and compare holdings across leveraged ETFs like PILL. These tools help surface relevant signals in the underlying pharmaceuticals names without replacing careful fundamental review. For investors focused on thematic or leveraged products, they can provide an efficient way to cross-check momentum and volatility metrics alongside traditional analysis.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Financial analyst and market blogger with expertise in equity research, fundamental analysis, and macroeconomic trends. I regularly publish coverage on individual stocks, ETFs, and sector developments — combining rigorous financial analysis with clear, engaging writing for a broad investment audience.
PILL saw its Momentum Indicator move below the 0 level on November 20, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 83 similar instances where the indicator turned negative. In 75 of the 83 cases, the stock moved further down in the following days. The odds of a decline are at 90%.
The Moving Average Convergence Divergence Histogram (MACD) for PILL turned negative on November 18, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 49 similar instances when the indicator turned negative. In 46 of the 49 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
PILL moved below its 50-day moving average on November 16, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PILL declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
PILL broke above its upper Bollinger Band on November 09, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where PILL's RSI Oscillator exited the oversold zone, 28 of 28 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 90%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.
The 10-day moving average for PILL crossed bullishly above the 50-day moving average on November 16, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 10 of 12 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 83%.
Following a +6.77% 3-day Advance, the price is estimated to grow further. Considering data from situations where PILL advanced for three days, in 288 of 311 cases, the price rose further within the following month. The odds of a continued upward trend are 90%.
The Aroon Indicator entered an Uptrend today. In 199 of 213 cases where PILL Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 90%.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows